The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study

Journal of the American College of Cardiology

Volumn 37, Issue 7, 2001, Pages 1775-1780

  Silverberg, Donald S ^a   Wexler, Dov ^a   Sheps, David ^a   Blum, Miriam ^a   Keren, Gad ^a   Baruch, Ron ^a   Schwartz, Doron ^a   Yachnin, Tatyana ^a   Steinbruch, Shoshana ^a   Shapira, Itzhak ^a   Laniado, Shlomo ^a   Iaina, Adrian ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROPOIETIN; FUROSEMIDE; HEMOGLOBIN; IRON; LOSARTAN; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 0035370037     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01248-7     Document Type: Article

References (43)

1. Pathogenesis of edema in chronic anemia: Studies of body water and sodium, renal function, haemodynamics and plasma hormones
2. The erythrocyte sedimentation rate in congestive heart failure
3. Iatrogenic congestive heart failure in older adults: Clinical course and prognosis
4. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
5. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations
6. Epidemiology and prevention of cardiac failure: Framingham study insights
7. Consensus recommendations for the management of chronic heart failure
8. Concomitant factors of decompensation in chronic heart failure
9. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks
10. Intravenous iron for the treatment of predialysis anemia
11. Intravenous ferric saccharate as an iron supplement in dialysis patients
12. A randomized controlled study of iron supplementation in patients treated with erythropoietin
13. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
14. Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: Validation of the technique and assessment of variability
15. Congestive heart failure hospitalizations and survival in California: Patterns according to race/ethnicity
16. Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction
17. Morbidity risk assessment in the surgically anemic patient
18. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity
19. Does transfusion practice affect mortality in critically ill patients?
20. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease
21. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients
22. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin
23. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry
24. Hematocrit level and associated mortality in hemodialysis patients
25. Hematocrit levels and hospitalization risks in hemodialysis patients
26. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the Studies Of Left Ventricular Dysfunction (SOLVD)
27. Mesangiolytic glomerulopathy in severe congestive heart failure
28. Elevated level of erythropoietin in congestive heart failure. Relationship to renal perfusion and plasma renin
29. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism
30. Progressive renal disease: The chronic hypoxia hypothesis
31. Early predictors of 15 year end-stage renal disease in hypertensive patients
32. Myocardial infarction is associated with renal function loss which is counteracted by ACE inhibition
33. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors
34. Relation of left ventricular diastolic properties to systolic function in arterial hypertension
35. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis
36. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease
37. Clinical predictors of heart failure in patients with first myocardial infarction
38. Erythropoietin modified the cardiac action of ouabain in chronically anaemic uraemic rats
39. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: Signal transduction pathways
40. Inactivation of erythropoietin leads to defects in cardiac morphogenesis
41. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients
42. Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta
43. Erythropoietin and systemic hypertension